

DAFTAR PUSTAKA

- Allen, S., Janda, W., Kaneman, E. & Winn, W., 2006.
Kaneman's Color Atlas and Textbook of Diagnostic Microbiology. 6th ed. s.l.:Lipincott Williams and Wilkins.
- Affolabi, D., Sanoussi, N., Odoun, M., Martin, A., Koukpemedji, L., Palomino, J. C., & Portaels, F. 2013. *Rapid low-cost identification of Mycobacterium tuberculosis complex using p-nitrobenzoic acid (PNB) as inhibitor and the resazurin microplate assay (REMA): A preliminary study*.
- American Thoracic Society. 1997. *Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacterium*. American Thoracic Society , 156:S1-S25.
- Andrews, J. M. 2001. *Determination of minimum inhibitory concentrations*. Journal of antimicrobial Chemotherapy, 48(suppl 1), 5-16.
- Barbara A. et al., 2012. *Antimicrobial Susceptibility Test, Drug Resistance Mechanism, and Therapy of*

Infections with Nontuberculous Mycobacterium.

Clinical Microbiology Review. 25(3):545-582.

Bhamidi S, Scherman M. S, & McNeil M. R., 2009.

Mycobacterial cell wall arabinogalactan: a detailed perspective on structure, biosynthesis, functions and drug targeting. Bacterial Polysaccharides: Current Innovations and Future Trends, 39-65.

Bieger, D., Hein, L., Lullman, H. & Mohr, K., 2005.

Color Atlas of Pharmacology. 3rd ed. s.l.:Thieme.

Bockstael, K., & Van Aerschot, A., 2009. *Antimicrobial resistance in bacteria.* Central European Journal of Medicine, 4(2), 141-155.

Brooks, G. F., Butel, J. S., Carroll, K. & Morse, S. A., 2007. *Jawetz, Melnick, & Adelberg's Medical Microbiology.* Chicago: The McGraw-Hill Companies, Inc.

Buijtelts, P.C.A.M, van der Sande, M.A.B, de Graaff, C, Parkinson, S, Verbrugh, H.A, Petit, P.L, van Soolingen, D, 2009. *Nontuberculous mycobacteria, Zambia.* Emerging Infectious Diseases (Print) 15, 242-249.

Carbon, C., 2000. *Comparison of side effects of
levofloxacin versus other fluoroquinolones.*

Chemotherapy, 47, 9-14.

Carrillo, C.S., Cotarelo, M., Cercenado, E., Vicente,
T., Blazquez, R., Bouza, E., 1996. *Comparative
invitro activity of sparfloxacin and eight
other antimicrobial agents against clinical
isolates of non tuberculous mycobacteria.* *Journal
of antimicrobial chemotherapy.* 37, 151-154.

Cassidy, P. M., Hedberg, K., Saulson, A., McNelly, E.,
& Winthrop, K. L., 2009. *Nontuberculous
mycobacterial disease prevalence and risk factors:
a changing epidemiology.* *Clinical Infectious
Diseases*, 49(12), e124-e129.

Chu, H. S., Chang, S. C., Shen, E. P., & Hu, F. R.,
2015. *Nontuberculous Mycobacterial Ocular
Infections—Comparing the Clinical and
Microbiological Characteristics between
Mycobacterium abscessus and Mycobacterium
massiliense.* *PloS one*, 10(1).

Cleveland Clinic, 2012. *Guidelines for Antimicrobial
Usage.* s.l.:Professional Communications, Inc.

De Groote, M.A., Pace, N.R., Fulton, K. and Falkinham, J.O., 2006. *Relationship between Mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils*. Appl Environ Microbiol 72, 7602-7606

Departemen Kesehatan Indonesia, 2011.

<http://www.depkes.go.id>.

[Online] Available at: <http://www.depkes.go.id/article/view/1444/tbc-masalah-kesehatan-dunia.html> [Accessed Agustus 2014].

Engelkirk PG, Duben-Engelkirk J. 2008. *Laboratory Diagnosis of Infectious Diseases: Essentials of Diagnostic Microbiology*. Lippincott Williams & Wilkins.

Gadre, D. V., Mahajan, M., Singh, N. R., Agarwal, D. S., & Talwar, V. 1995. *Niacin test for mycobacteria: a comparative study of two methods*. Indian Journal of Tuberculosis, 42, 225-226.

Gold, H. S., & Moellering Jr, R. C. 1996. *Antimicrobial-drug resistance*. New England Journal of Medicine, 335(19), 1445-1453.

Griffithh, D.E., Aksamit, T., Brown-Elliott, B.A.,
Catanzaro,A.,Daley, C., Gordin, F., Holland, S.M.,
Horsburgh, R. et al., 2007. An official ATS / IDSA
statement: diagnosis, treatment,and prevention of
nontuberculous mycobacteriadiseases. Am J Respir
Crit Care Med 175, 367-416.

Hett EC, Rubin EJ., 2008. *Bacterial Growth and Cell
Division: a Mycobacterial Perspective*. Microbiol.
Mol. Biol. Rev. 72(1):126. DOI:10.1128/MMBR.00028-
07.

Hong-xiu, W., 2010. *Nontuberculous
mycobacteria:susceptibility pattern and prevalence
rate in Shanghai from 2005 to 2008* 123, 184-187.

Horsburgh CR., 1996. *Epidemiology of disease caused by
nontuberculous mycobacteria*. Semin Respir Infect
11:244-51.

Huang, C.-W., Chen, J.-H., Hu, S.-T., Huang, W.-C.,
Lee, Y.-C., Huang, C.-C., Shen, G.-H., 2013.
*Synergistic activities of tigecycline with
clarithromycin or amikacin against rapidly growing
mycobacteria in Taiwan*. Int. J. Antimicrob. Agents
41, 218-23.

Hudzicki, J., 2012. *Kirby-Bauer disk diffusion susceptibility test protocol*. American society for microbiology.

Huitt, Gwen A., Michael D. Iseman, and C. A. Peloquin., 2014. *Malabsorption of anti-tuberculosis medications by a patient with AIDS*. England Medical journal 327 (1992): 1817-8.

Ioachimescu, Octavian C., and M. S. Kavuru., 2006. *Pulmonary alveolar proteinosis*. Chronic respiratory disease 3.3: 149-159.

Jesudason, MV, and Gladstone P., 2005. *Non Tuberculous Mycobacteria Isolated From Clinical Specimens At A Tertiary Care Hospital In South India*. Indian J Med Microbiol 23.3: 172.

Jorgensen, J.H., Ferraro, M.J., 2009. *Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices and the rational performing*. 7750, 1749-1755

Joyce G, Williams KJ, Robb M, Noens E, Tizzano B, Shahrezaei, Robertson BD., 2012. *Cell Division Site Placement and Asymmetric Growth in Mycobacteria*. PLoS ONE. 7(9):e44582. doi:10.1371/journal.pone.0044582..

- Jing, H., Wang, H., Wang, Y., Deng, Y., Li, X., Liu, Z., & Ma, X., 2012. *Prevalence of nontuberculous mycobacteria infection, China, 2004-2009*. *Emerging infectious diseases*, 18(3), 527-528.
- Katoch, V. M., 2004. *Infections due to non-tuberculous mycobacteria (NTM)*. *Indian Journal of Medical Research*, 120, 290-304.
- Katzung BG, Masters SB, Trevor AJ., 2012. *Basic & Clinical Pharmacology*. 12th ed. McGraw Hill.
- Kawata, K., Illarionov, P., Yang, G. X., Kenny, T. P., Zhang, W., Tsuda, M., & Gershwin, M. E., 2012. *Mincle and human B cell function*. *Journal of autoimmunity*, 39(4), 315-322.
- Klemens, S. P., Cynamon, M. H., Swenson, C. E., & Ginsberg, R. S., 1990. *Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice*. *Antimicrobial agents and chemotherapy*, 34(6), 967-970.
- Koh, W. J., Yu, C. M., Suh, G. Y., Chung, M. P., Kim, H., Kwon, O. J., ... & Lee, K. S., 2006. *Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum*. *The International Journal of Tuberculosis and Lung Disease*, 10(9), 1001-1007.

Kiser KM, Payne WC, Taff TA. 2012. *Clinical Laboratory Microbiology: A Practical Approach*. Pearson.

Lalitha, P., Rhatinam, S.R., and Srinivasan, M., 2004. *Ocular Infections Due To Non-Tuberculous Mycobacteria*. Indian Journal of Medical Microbiology 22.4: 23.

Lazo, J. S., & Parker, K. L., 2005. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill Publishing.

Lehmann, K.B., Neumann, R., 1896. *Atlas und Grundriss der Bakteriologie und Lehrbuch der speziellenbakteriologischen Diagnostik*. 1st ed. J.F.Lehmann, Munchen.

Li, G., Lian, L., Wan, L., Zhang, J., Zhao, X., et al., 2013. *Antimicrobial Susceptibility of StandardStrains of Nontuberculous Mycobacteria byMicroplate Alamar Blue Assay*. Plos one. 8, 1-5.

Morgan D., 2007. The Cell Cycle: Principals of Control. London: New Science Press LTD.

Murray, P. R., Rosenthal, K. S. & Pfaller, M. A., 2009. *Medical Microbiology*. 6th ed. s.l.:Mosby Elsevier.

Neal, M. J., 2002. *Medical Pharmacology at a Glance*. 4th ed. s.l.:Blackwell Science.

Neal, M.J., 2005. At a Glance Farmakologi Medik. Edisi kelima. Jakarta: Penerbit Erlangga. Hal: 84-85.

Park, S., Kim, S., Park, E. M., Kim, H., Kwon, O. J., Chang, C. L., Lew, W. J., Park, Y. K., Koh, W., 2008. *In Vitro Antimicrobial Susceptibility Of Mycobacterium Abscessus In Korea*. Journal of Korean Medical Science 23.1: 49.

Popat, K. C., Eltgroth, M., LaTempa, T. J., Grimes, C. A., & Desai, T. A., 2007. *Decreased Staphylococcus epidermis adhesion and increased osteoblast functionality on antibiotic-loaded titania nanotubes*. Biomaterials, 28(32), 4880-4888.

Rastogi, N., Goh, K. S., Bryskier, A., & Devallois, A., 1996. *Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine*. Antimicrobial agents and chemotherapy, 40(11), 2483-2487.

Ripoll, F., Pasek, S., Schenowitz, C., Dossat, C., Barbe, V., Rottman, M., & Gaillard, J. L. 2009. *Non mycobacterial virulence genes in the genome of*

*the emerging pathogen Mycobacterium
abscessus. PloS one, 4(6), e5660.*

Ryan, KJ & Ray, CG., 2010. Sherris Medical Microbiology
(4th ed.). McGraw Hill.

Set, R., Rokade, S., Agrawal, S. Shastri, J., 2010.
*Antimicrobial Susceptibility Testing Of Rapidly
Growing Mycobacteria By Microdilution - Experience
Of A Tertiary Care Centre. Indian J Med Microbiol
28.1. 48.*

Silva, P.E.A., Palomino, J.C., 2011. *Molecular basis
and mechanis of drug resistance in mycobacterium
tuberculosis: classical and new drugs.*
JAntimicrobial Chemother. 66, 1417-1430.

Sjahrurachman, A., 2011. Cara genetis untuk menentukan
kepekaan bakteri terhadap antibiotik. Bagian
mikrobiologi FKUI. 38, 498-502.

Stockley, I.H., 1994. *Drug Interactions a Source Book
of Adverse Interaction, Their Mechanisms, Clinical
Importance and Management Adverse Interaction.*
Third Edition England. Hal: 131-135.

Soini, H., & Musser, J. M. 2001. *Molecular diagnosis of
mycobacteria. Clinical Chemistry, 47(5), 809-814.*

Swenson J. M., Thornsberry C., Silcox V.A., 1982.

*Rapidly Growing Mycobacteria: Testing of
Susceptibility to 34 Antimicrobial Agents by Broth
Microdilution. Antimicrobial Agents and
Chemotherapy. 22(2):186- 192.*

Swenson, J. M., Wallace, R. J., Silcox, V. A., &

Thornsberry, C., 1985. *Antimicrobial
susceptibility of five subgroups of Mycobacterium
fortuitum and Mycobacterium chelonae.*
Antimicrobial agents and chemotherapy, 28(6), 807-
81.

Tortoli, E., 2009. *Clinical manifestations of
nontuberculous mycobacteria infections.* European
Society of Clinical Microbiology and Infectious
Diseases. 15: 906-910.

World Health Organization, 2012. www.who.int [Online]

Available

at:http://www.who.int/tdr/publications/global_repo
rt/en/[Accesed September 2014].

Wikler, M. A. 2006. *Performance standards for
antimicrobial susceptibility testing: Sixteenth*

informational supplement (Vol. 26). Clinical and
Laboratory Standards Institute.